MORRIS PLAINS, N.J., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced the issuance of U.S. Patent 9,492,566, the 32 nd U.S. patent protecting the use of sacituzumab govitecan (IMMU-132), the Company's lead antibody-drug conjugate (ADC), for the treatment of patients with Trop-2-positive cancers. In an ongoing Phase 2 clinical study, sacituzumab govitecan has produced encouraging objective response rates and durable responses in heavily-pretreated patients with metastatic triple-negative breast (TNBC), small-cell and non-small-cell lung, and urothelial cancers. The promising results in solid cancers have motivated the Company to expand its ADC program to include liquid tumors. Using the same CL2A linker and the SN-38 toxic payload, the Company created IMMU-140, the subject of U.S. Patent 9,493,573 issued for additional claims under the patent family, "Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity." The parent antibody in IMMU-140 is an anti-HLA-DR IgG4 antibody (IMMU-114) that has demonstrated evidence of treatment responses in more than 50% of assessable patients in a Phase 1 study in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) without reaching a maximum tolerated dose. At the Annual Meeting of the American Society of Hematology, to be held December 3-6, 2016, the Company will present preclinical results on in vitro and in vivo activity of IMMU-140 in animal models of five liquid cancers, NHL, CLL, acute myelocytic and lymphocytic leukemia, and multiple myeloma. The Company has also created yet another ADC targeting B-cell hematologic malignancies. Protected by the new U.S. Patent 9,493,574 under the same patent family of "Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity," this new ADC comprises a humanized anti-CD19 antibody, hA19, conjugated to SN-38. All three new ADC patents will expire in July 2033. "We are pleased to receive these new patents, which provide extensive intellectual property protection for our robust ADC program that has the potential to address approximately 90% of all human cancers based on the number of estimated new cases in the U.S., as compiled by the American Cancer Society," commented Cynthia L. Sullivan, President and Chief Executive Officer.